Assignee
CAMURUS AB
SE23 patents
Top patents by PatentIndex Score
US9585959B2Mar 7, 2017
Robust controlled-release formulations
CAMURUS AB16 citations92
US9526788B2Dec 27, 2016
Pharmaceutical lipid compositions
CAMURUS AB8 citations84
US10912772B2Feb 9, 2021
Opioid formulations
CAMURUS AB4 citations83
US9937164B2Apr 10, 2018
Opioid formulations
CAMURUS AB7 citations83
US10688148B2Jun 23, 2020
Formulations containing a somatostatin receptor agonist
CAMURUS AB7 citations82
US9968680B2May 15, 2018
Topical bioadhesive formulations
CAMURUS AB5 citations82
US9555118B2Jan 31, 2017
Robust controlled-release peptide formulations
CAMURUS AB5 citations73
US11135215B2Oct 5, 2021
Opioid formulations
CAMURUS AB3 citations72
US11110084B2Sep 7, 2021
Opioid formulations
CAMURUS AB2 citations72
US11564968B2Jan 31, 2023
Formulations containing a somatostatin receptor agonist
CAMURUS AB1 citations71
US11241476B2Feb 8, 2022
Mixtures and formulations comprising an alkyl ammonium EDTA salt
CAMURUS AB1 citations71
US11135264B2Oct 5, 2021
Formulations containing a somatostatin receptor agonist
CAMURUS AB3 citations71
US9649382B2May 16, 2017
Topical bioadhesive formulations
CAMURUS AB5 citations71
US5260282ANov 9, 1993
Saliva substitute
CAMURUS AB16 citations66
US5001062AMar 19, 1991
Antithrombogenic article containing lysozyme and heparin adsorbed on a substrate
CAMURUS AB16 citations65
US12396944B2Aug 26, 2025
Injectable buprenorphine formulation
CAMURUS AB0 citations62
US12318379B2Jun 3, 2025
Opioid formulations
CAMURUS AB0 citations62
US12161640B2Dec 10, 2024
Opioid formulations
CAMURUS AB1 citations62
US12029813B2Jul 9, 2024
Injectable buprenorphine formulation
CAMURUS AB1 citations62
US11672843B2Jun 13, 2023
Somatostatin receptor agonist formulations
CAMURUS AB1 citations62
US12257282B2Mar 25, 2025
Mixtures and formulations
CAMURUS AB0 citations61
US11369617B2Jun 28, 2022
Prostacyclin analogue formulations
CAMURUS AB0 citations61
US12246055B2Mar 11, 2025
Lipid-controlled release compositions
CAMURUS AB0 citations47